HISTOPATHOLOGY INDIA.COM  Atypical Fibroxanthoma 

              Dr Sampurna Roy MD

 
 

Histopathology Image of Ductal Adenocarcinoma of the Pancreas:         

                  

 Visit: Pancreatic Pathology Online ;

Exocrine Pancreatic Tumours.

Ductal adenocarcinoma accounts for about 80-90% of

malignant exocrine tumours.

Etiology: Etiology is complex and probably multifocal, although

smoking and a high intake of dietary fat seem important.

Familial causes are rare but pancreatic ductal

adenocarcinoma may occur in some families with

history of cancer.

Age and sex : Mostly seen over 50 years of age.

Male: female ratio is 1.5  : 1.0

Sites and clinical features:

1. Head (two-thirds of the cases)- causes obstruction of the

biliary tract with jaundice and occlusion of the main

pancreatic duct leading to obstructive

pancreatitis.

2. Tail, uncinate process or in combined sites:

Patients present with pain and weight loss or liver metastases

from an "occult" primary.

Spread:

- Local spread: depends on the location of the tumour

and include:

From head:  bile duct, duodenum and retroperitoneum.

From tail: peritoneum, stomach, colon, spleen and left adrenal.

- Lymphatic spread:

To the Peri -pancreatic lymph nodes ;

To the regional lymph nodes (in the hepatoduodenal ligament 

up to the ciliac trunk) in about 50% of cases.

( "Juxta-regional " - mainly para-aortic lymph nodes

in about 10% of cases).

- Blood-borne metastases:  To the liver, lungs, pleura and bone.

Gross features :

Head:  Generally "solid", poorly demarcated, hard, yellowish-

white to gray, often about the size of  2-5 cm in diameter.

Hemorrhage, necrosis, and cystic change is rare except in

very large cancer.

Body or tail:  Diffuse growth spreading in the parenchyma. 

Average size is about  5-7 cm or more.  

Pathological staging (TNM classification ):

I - Based on the size of the primary tumor:(pT1-pT4)

II - Presence or absence of regional metastatic lymph nodes

(pN1a or pN1b), if multiple lymph nodes are involved.

III - Distant metastases (pM).

Microscopic features:

1. Well to moderately differentiated tumours :

Consists of tubular and glandular structures lined by

mucus-secreting columnar cells arranged in a single regular

layer, but may show stratification and papillary projection.

There is a marked desmoplastic reaction, with formation of

dense fibrous tissue.

2. Moderately and poorly differentiated tumours:  

Consists of poorly formed glands with decreased mucus

secretion.

Pleomorphism and mitotic figures are present.

Immunohistochemical findings:

1. Antibodies to cytokeratin 7, 8, 18, and 19.

2. Epithelial Membrane Antigen (EMA)

3. Carcinoembryonic Antigen (CEA)

4. DUPAN-2.

Ultrastructural findings:

The majority of ductal adenocarcinomas show K-ras and

P53 mutations, which differentiate it from mucinous cystic

tumours, acinar cell carcinomas, and endocrine tumours,

all of which lack these mutations.

Differential diagnosis:      

 Chronic Pancreatitis :

1. Usually reveals remnants of lobules embedded in

fibrotic tissue.

2. Remaining ducts may be dilated or atrophic.

3. Ductal epithelium may be atrophic or hyperplastic.

4. Calcification and proteinaceous plugs in the ducts are common.

Prognosis:

Death within 3 years - 90% of cases.

5-year survival  is 1 to 5%.

                   

Long-term results after radical resections for pancreatic ductal adenocarcinoma--10 years experience. Rozhl Chir. 2007;86(4):174-9.

INTRODUCTION: Pancreatic ductal adenocarcinoma is the most often and the most malignant type of pancreatic tumor. Effective systemic anticancer treatment is still missing and only radical resection can potentially lead to the life prolongation. TARGET: Long-term therapeutic outcomes evaluation in patients after radical resections due to the pancreatic ductal adenocarcinoma during the 10 years period. MATERIAL AND METHODS: Population included 42 patients after resection of pancreas due to ductal adenocarcinoma realized during the period from 1995 to 2005. Therapeutic outcomes including long-term survival in different stages of the disease were compared with data collected from patients with another histological type of periampullar tumor by statistical analysis. RESULTS: 48 radical resections of pancreas due to ductal adenocarcinoma were realized during the 10 years period. Six patients were excluded from the follow up. Median of survival with the minimum 6 months of follow up has reached 14 months and the maximal survival time was 35 months. None of the patients has survived 5 years. Five patients were alive after the end of follow up period. There were no statistical difference in survival when particular disease stages were compared (p = 0.3226). Survival of female patients in this population was statistically lower in comparison to male patients (p = 0.0222). Significantly lower survival of patients with ductal adenocarcinoma in comparison to the patients with other types of carcinoma in periampullar localization was demonstrated (p = 0.0234). CONCLUSION: Achieved results proved that pancreatic carcinoma is solid tumor with the worst long-term prognosis. Long-term survival in this population did not exceed 35 months and was independent on per-operative staging. Long-term prognosis of ductale adenocarcinoma is significantly worse in comparison to other types of carcinoma in periampullar localization.

Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma.Pancreas. 2006;32(3):281-7.

OBJECTIVES: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is an indolent neoplasm by nature; however, it sometimes acquires invasive potential and has been classified as invasive IPMN. The aim of the present study was to investigate the clinicopathologic difference between invasive IPMN and a common type of invasive ductal carcinoma of the pancreas. METHODS: Eighteen patients with invasive IPMN underwent pancreatectomy between 1992 and 2004. Clinical, biochemical, and histopathologic factors were retrospectively analyzed. The resulting data were compared with those of 274 patients with a common type of pancreatic ductal carcinoma who underwent surgery during the same period. RESULTS: The total size of tumor of invasive IPMN, including cystic and invasive components, was statistically larger than that of a common type of invasive ductal carcinoma (62 vs 40 mm, P < 0.001), but the size of invasive component of invasive IPMN was smaller than that of a common type of invasive ductal carcinoma (21 vs 40 mm, P < 0.001). Negative lymph node metastases and relatively limited local tumor spreading were frequently observed in patients with invasive IPMN. On microscopic examination, the tumors infiltrating the surrounding tissue had a less invasive growth pattern, and a lower frequency of lymphatic invasion, venous invasion, and intrapancreatic neural invasion was also observed in patients with invasive IPMN. The 5-year survival rate of invasive IPMN was significantly higher than that of common-type invasive ductal carcinoma (42% vs 20%, P = 0.04). CONCLUSIONS: An increased awareness of invasive IPMN has enabled pancreatectomies to be performed at an earlier stage, relative to that for ordinary pancreatic cancer. The less frequent detection of pathological factors concerned with tumor invasiveness in patients with invasive IPMN suggested the lower aggressive behavior of this tumor.

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors.Ann Surg. 1996;223(3):273-9.

OBJECTIVE: The authors reviewed the clinicopathologic characteristics of patients who underwent resection with curative intent for ductal adenocarcinoma of the pancreas between 1983 and 1989. SUMMARY BACKGROUND DATA: Recent studies have demonstrated a reduction in the morbidity and mortality of pancreatic resection and improvement in the actuarial 5-year survival for patients with resected ductal adenocarcinoma. METHODS: Resection with curative intent was performed on 118 of 684 patients (17%) with pancreatic cancer admitted to the authors' institution. Clinical, demographic, treatment, and pathologic variables were analyzed. The original material for all cases was reviewed; nonductal cancers were excluded. RESULTS: The head of the gland was the predominant tumor site (n = 102), followed by the body (n = 9), and tail (n = 7). Seventy-two percent of the patients underwent pancreaticoduodenectomies, 15% underwent total pancreatectomies, 10% underwent distal pancreatectomies, and 3% underwent distal subtotal pancreatectomies. Operative mortality was 3.4%. Median survival was 14.3 months after resection compared with 4.9 months if patients did not undergo resection (p < 0.0001). Twelve patients survived 5 years after surgery (10.2% overall actual 5-year survival rate). Three of the tumors were well differentiated, five were moderately differentiated, and four were poorly differentiated. Extrapancreatic invasion occurred in nine cases (75%), and perineural invasion was present in ten cases (83%). Five tumors exhibited invasion of duodenum, ampulla of Vater, and/or common bile duct, and an additional tumor invaded the portal vein. Lymph node involvement by carcinoma was noted in five cases (42%). Six patients remain alive without evidence of disease at a median follow-up of 101 months (range, 82-133 months). Five patients died of recurrent or metastatic pancreatic cancer at 60, 61, 62, 64, and 64 months, respectively. One patient died at 84 months of metastatic lung cancer without evidence of recurrent pancreatic disease. CONCLUSIONS: This paper emphasizes the grim prognosis of pancreatic ductal adenocarcinoma. Five-year survival cannot be equated to cure. Although pancreatectomy offers the only chance for long-term survival, it should be considered as the best palliative procedure currently available for the majority of patients. This emphasizes the need for the development of novel and effective adjuvant therapies for this disease.

                   

 
November  2009

Histopathology-India.net

diagnostichistopathology. blogspot.com

Pathopedia-India.com

Surgical-Pathology.com

Pathology-India.com

Pancreatic Pathology Online

Gall Bladder Pathology Online

Paediatric Pathology Online

Paraganglioma-Online

Endocrine Pathology Online

Eye Pathology Online

Ear Pathology Online

Cardiac Path Online

Lung Tumour-Online

Mesothelioma-Online

Pulmonary Pathology Online

Nutritional Pathology Online

Environmental Pathology Online

Pathology Quiz Online

Dermpath-India

GI Path Online

Soft Tissue Pathology

Case Index

Infectious Disease Online; INDEX: A-D ; INDEX: E-L ; INDEX: M-P INDEX: Q-Z ; FUNGAL DISEASE ; VIRAL DISEASE.

E-book - History of  Medicine with special reference to India.

Basic Pathology Blog

Ductal adenocarcinoma of the pancreas: clinicopathologic features and survival.Tumori. 1993 Oct 31;79(5):325-30.

AIMS AND BACKGROUND: The prognosis after surgical resection for pancreatic cancer has not been clearly defined because conflicting results have been reported. METHODS: Fifty-five patients who underwent surgical resection for pancreatic carcinoma between 1970 and 1987 were retrospectively reviewed to determine factors influencing long-term survival. RESULTS: The actuarial 5-year survival rate for all 55 patients was 12.5%. Type of operation, tumor stage, direct extension into adjacent organs, grading and lymph node involvement were found to significantly influence survival. Age, sex, tumor site, size, invasion into peripancreatic tissue, invasion of lymphatic vessels and small veins, perineural infiltration, tumor necrosis, round cell infiltrate at the tumor margin, associated chronic pancreatitis, and atypia of pancreatic ductal epithelium demonstrated no predictive capacity. No 5-year survival was observed among the patients who underwent vascular resection. Three of 9 patients who underwent left-sided pancreatectomy for cancer of the tail of the pancreas survived more than 5 years. Multivariate analysis confirmed that lymph node involvement, moderate-poor histologic tumor differentiation, and treatment with total pancreatectomy were significantly associated with a worse prognosis. CONCLUSIONS: Lymph node status, grading of the tumor and type of operation have a significant impact on prognosis in resected pancreatic cancer.

Anatomy of Normal Pancreas

Normal Islets of Langerhans

An approach to reporting of pancreatic specimen

Reporting of pancreatic biopsies for the diagnosis of neoplastic lesions

Reporting of ampullary and periampullary biopsies for the diagnosis of neoplastic lesions

Reporting of Pancreatico duodenectomy (Whipple's operation) specimen

Reporting of Distal Pancreatectomy Specimen

Developmental Defects of Pancreas

Nesidioblastosis

Pancreas Divisum

AberrantPancreas

Annular Pancreas

Pancreatic Agenesis

Non-Neoplastic Pancreatic Cysts 

Pancreatitis

Acute Pancreatitis

Chronic Pancreatitis

Autoimmune Pancreatitis

Herpes Simplex Pancreatitis

Diabetes Mellitus

Non-Neoplastic Tumour-Like Lesions (Pseudotumour) of the Pancreas

Neoplasms of the Endocrine Tumours

Islet Cell Tumours

Glucagonomas

Insulinomas

Somatostatinoma

Enterochromaffin Cell (Carcinoid) Tumours

Pancreatic Gastrinoma

Multiple Endocrine Neoplasia (MEN) Syndrome

Pyloric Gland Adenoma

Carcinoma of the Pancreas

Contrasting histopathological features of obstructed pancreas and pancreatic adenocarcinoma

Cystic Tumours of the Pancreas

Paediatric Pancreatic Tumours

Pancreatic Intraepithelial Neoplasia

Adenosquamous carcinoma 

Acinar cell carcinoma

Pancreatoblastoma

Intraductal Papillary Mucinous Tumour

Mucinous Cystic Tumours

Serous Cystic Tumours

Solid Pseudopapillary Tumour

Mucinous Non-Cystic and Signet-Ring Cell Carcinoma

Undifferentiated (anaplastic) carcinoma

Undifferentiated carcinoma with osteoclast-like giant cell

Oncocytic carcinoma

Clear cell carcinoma

Microglandular adenocarcinoma

Carcinoma with mixed differentiation

Small cell carcinoma

Non Epithelial Tumours of the Pancreas

Clear Cell (Sugar) Tumour of the Pancreas

Pancreatic Schwannoma


                            Disclaimer  Privacy Policy  ; Advertising Policy  ;  E-mail  .         

                Copyright © 2009  surgical-pathology.com
            All rights reserved